In a clinical trial conducted by Sethi et al., CD133 cancer cells from SCLC patients resistant to the chemotherapeutic agent etoposide were treated with a V1a receptor blocker called peptide 1 and it was noted that these CD133 cancer cells which were resistant to etoposide now became sensitive (51). This evidence concerns the gene PROM1 and cancer.